EUVIMEDEUVIMED entdecken
Crossref

Antithrombotic prophylaxis in patients treated with Bruton’s tyrosine kinase inhibitors

Sebastian Szmit

Hematology in Clinical Practice · 2023

DOI: 10.5603/hcp.2023.0006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology in Clinical Practice, 2023. Verfasst von Sebastian Szmit.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is an increased risk of atrial fibrillation in patients treated with Bruton’s tyrosine kinase inhibitors such as ibrutinib or acalabrutinib. The risk of this complication, as in the general population, increases with the age of patients and the coexistence of cardiovascular diseases. Due to the observed platelet dysfunction associated with the activity of ibrutinib, antithrombotic prophylaxis against stroke becomes an important clinical problem. The presence of potential interactions between ibrutinib and oral anticoagulant and additionally increased risk of bleeding determine specific therapeutic choices, which are described in the article.

Zitieren

APA

Szmit, S. (2023). Antithrombotic prophylaxis in patients treated with Bruton’s tyrosine kinase inhibitors. Hematology in Clinical Practice. https://doi.org/10.5603/hcp.2023.0006

Vancouver

Szmit S. Antithrombotic prophylaxis in patients treated with Bruton’s tyrosine kinase inhibitors. Hematology in Clinical Practice. 2023. doi:10.5603/hcp.2023.0006

BibTeX
@article{Szmit2023,
  author = {Szmit, Sebastian},
  title = {Antithrombotic prophylaxis in patients treated with Bruton’s tyrosine kinase inhibitors},
  journal = {Hematology in Clinical Practice},
  year = {2023},
  doi = {10.5603/hcp.2023.0006}
}
Kostenlos starten →